amarna signature
Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development
03 déc. 2024 16h10 HE | Amarna Therapeutics
Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development Leiden, The Netherlands, 3 December 2024 - Amarna Therapeutics, (“Amarna” or “the Company”), a...
Transparency Market Research
Multiplex Assays Market Size & Share to Surpass USD 5.9 billion by 2031 | Analysis by Transparency Market Research, Inc.
04 nov. 2024 02h42 HE | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The global multiplex assays market (멀티플렉스 분석 시장) is estimated to be valued at US$ 5.9...
Poltreg_logo_kolor.jpg
PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes
24 oct. 2024 01h00 HE | PolTREG S.A.
                Treating diabetes patients earlier with PTG-007 could provide functional cureRecruitment will go ahead after European Medicines Agency approvalCompany has 12 years’ worth of safety...
GMILogo_Vertical-Gradient.png
Tumor Necrosis Factor Inhibitor Drugs Market to hit USD 50 billion by 2032, says Global Market Insights Inc.
02 oct. 2024 05h42 HE | Global Market Insights Inc.
Selbyville, Delaware, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Tumor Necrosis Factor Inhibitor Drugs Market size valued at USD 41.3 billion in 2023 and is projected to grow at a CAGR of 2.2% from...
Poltreg_logo_kolor.jpg
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
26 sept. 2024 01h00 HE | PolTREG S.A.
Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate developmentNew CAR-Treg cell therapy...
Poltreg_logo_kolor.jpg
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
16 sept. 2024 01h00 HE | PolTREG S.A.
China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to...
Poltreg_logo_kolor.jpg
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
09 sept. 2024 01h00 HE | PolTREG S.A.
PTG-007 cell therapy resulted in clinical remission in some patients for up to 12 yearsA proportion of patients remained insulin-independent for up to 24 monthsPTG-007 ready to enter pivotal studyData...
SciRhom Leadership Team
SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases
09 juil. 2024 02h00 HE | SciRhom GmbH
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary...
Logo.png
GRI Bio Regains Compliance with Nasdaq
08 juil. 2024 09h05 HE | GRI Bio, Inc.
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
Poltreg_logo_kolor.jpg
PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years
24 juin 2024 01h30 HE | PolTREG S.A.
                 PTG-007 administration resulted in improved remission and insulin secretion Patients monitored for up to 12 yearsPlanned pivotal Phase 2/3 study is final step for PolTREG to...